Telehealth Peptide Prescribing Regulation: Where the Law Stands in May 2026

The regulatory environment for telehealth-enabled peptide prescribing has become dramatically more restrictive in 2026 compared to the COVID-era flexibility that enabled rapid growth of the peptide wellness market. DEA special registration for telemedicine-based controlled substance prescribing, state medical board tele-prescribing standards that require in-person evaluation for certain substances, and FDA's enforcement posture on compounded semaglutide are collectively reshaping which telehealth business models are viable. For organizations in regulatory compliance and the broader peptide industry, understanding the current legal framework is essential for compliance planning.

The COVID Telehealth Exception: Expiration and Legacy

The 2020 COVID-19 public health emergency (PHE) created extraordinary telehealth flexibility at both federal and state levels. At the federal level, DEA waived the requirement for an in-person evaluation before prescribing controlled substances via telemedicine, allowing Schedule II-III controlled substance prescriptions (including human growth hormone, which is Schedule III) based on audio-visual telemedicine visits. Many states made parallel regulatory changes.

This PHE flexibility was the foundation on which telehealth peptide prescribing platforms scaled. By 2022-2023, dozens of platforms were prescribing GHS peptides, GLP-1 analogs, and related substances via telehealth encounters conducted entirely by non-physician practitioners in states with expanded practice authority, to patients who had never had any in-person evaluation.

The PHE ended May 11, 2023. The federal DEA telemedicine prescribing flexibilities have been extended through temporary rules while DEA develops a permanent telemedicine special registration framework, but the direction of travel is clear: the pandemic-era unlimited telehealth prescribing flexibility will not continue permanently.

DEA Telemedicine Special Registration: The Current Status

DEA published an Interim Final Rule in 2023 proposing a telemedicine special registration framework, received extensive public comment, and has continued refining the framework through 2024-2025. The current regulatory status as of May 2026:

Temporary extensions remain in effect for practitioners who were prescribing controlled substances via telemedicine before the COVID PHE ended and who have registered with DEA as required. These extensions continue to allow prescribing via telemedicine without the in-person evaluation requirement, but only for practitioners who were in the telemedicine prescribing practice before the PHE ended and who are complying with ongoing registration requirements.

New telemedicine prescribers who did not have telemedicine-based controlled substance prescribing relationships before the PHE ended are subject to new standards that have not yet been finalized in a permanent rule. DEA's interim framework has been subject to legal challenge and ongoing negotiation, creating continuing uncertainty.

Practical implications for peptide platforms: Telehealth companies that were prescribing human growth hormone (Schedule III) or other controlled substances via telemedicine before PHE end and that have complied with DEA's registration requirements are in a different regulatory position than companies that began telemedicine controlled substance prescribing after PHE end. Companies whose practitioners have not maintained DEA compliance with telemedicine prescribing requirements face enforcement risk.

State Medical Board Standards for Telehealth Prescribing

Independent of the federal DEA framework, state medical boards regulate the standard of care for prescribing, including telehealth prescribing. Multiple states have adopted or enforced standards that require certain pre-prescribing elements that the purely online, questionnaire-driven telehealth model cannot satisfy:

In-person physical examination requirements. Several states require that prescribers perform or review an in-person physical examination as a condition of prescribing certain substances. For human growth hormone and other controlled substances with specific medical indications (FDA-approved HGH is indicated only for specific growth failure and wasting conditions), prescribing via telemedicine without a documented physical examination meeting state standards creates medical board exposure.

Prescriber-patient relationship requirements. Many states' medical practice acts define a prescriber-patient relationship that requires more than a questionnaire response, typically including a real-time audio-visual encounter with sufficient history-taking to establish a bona fide prescriber-patient relationship. Some state boards have found that platforms relying on pre-filled questionnaires without real-time prescriber-patient interaction do not meet this standard.

Nurse practitioner and PA prescribing authority limitations. The expanded use of nurse practitioners and physician assistants as prescribers on telehealth platforms has run into state-specific scope-of-practice limitations. Some states limit NP prescribing authority for controlled substances to circumstances involving a collaborating physician. Platforms that rely heavily on NP prescribers need to audit their compliance with state-specific NP prescribing authority rules.

The Compounding Prohibition Dimension

For telehealth platforms that depend on prescriptions being filled by 503A compounding pharmacies, the FDA compounding restrictions discussed separately in recent regulatory compliance coverage add a separate compliance dimension. A telehealth prescription for compounded semaglutide written after FDA removed semaglutide from the drug shortage list creates liability exposure for both the prescriber and the dispensing pharmacy. Telehealth companies that continued prescribing compounded semaglutide after the shortage list removal may face regulatory action both from DEA/state boards (for prescribing violations) and from FDA (for facilitating illegal drug compounding).

Platform Business Model Implications

The regulatory environment changes are fundamentally reshaping viable telehealth business models in the peptide space:

Models under pressure:

• Questionnaire-only prescription models (no real-time prescriber-patient encounter)
• Models that prescribe compounded semaglutide or tirzepatide post-shortage-list-removal
• Models relying on NP/PA prescribers in states where their authority for the relevant substances is restricted
• Models with inadequate DEA compliance documentation for telemedicine controlled substance prescribing

More viable models:

• Platforms prescribing FDA-approved peptide products (not compounded analogs) through qualified prescribers meeting state standard-of-care requirements
• Hybrid models that incorporate initial in-person evaluation before transitioning to telehealth follow-up
• Models focused on non-controlled-substance peptide prescribing where DEA telemedicine restrictions don't apply
• Models with robust prescriber credentialing, medical record documentation, and state-specific compliance review

Enforcement Actions in Q1-Q2 2026

The regulatory agencies have moved from warning signals to active enforcement in Q1-Q2 2026:

DEA. Multiple DEA enforcement actions in the first half of 2026 have targeted telehealth practitioners and platforms for controlled substance prescribing violations. These have included civil monetary penalties, DEA registration revocations, and criminal referrals for the most egregious cases.

State medical boards. In addition to the pharmacy board actions covered separately, state medical boards have opened investigations and issued cease-and-desist notices to prescribers associated with non-compliant telehealth platforms. The pattern enforcement model, coordinated actions against practitioners associated with specific platforms rather than one-off complaint-driven investigations, appears to be accelerating.

FTC. The Federal Trade Commission has been monitoring telehealth marketing practices, including claims made by peptide telehealth companies about compounded GLP-1 product equivalence to FDA-approved drugs. FTC enforcement in this area is a distinct risk channel from DEA and state board enforcement.

What Compliant Platforms Are Doing

Telehealth platforms that are navigating the compliance environment successfully share several characteristics:

1. In-house or retained regulatory affairs counsel who maintains current knowledge of federal and state-specific prescribing requirements and proactively identifies changes affecting platform compliance.

2. Prescriber credentialing and training programs that ensure all prescribers on the platform understand and comply with applicable standards, including state-specific requirements.

3. Medical record documentation systems that generate compliant encounter records demonstrating that prescribing met applicable standards, not just questionnaire responses, but documented clinical reasoning.

4. Product formulary aligned with current regulatory permissibility, prescribing FDA-approved products where available, and limiting compounding to genuinely eligible substances with documented shortage analysis.

5. State-by-state compliance review that identifies high-risk jurisdictions and adjusts platform operations accordingly.

For organizations in workforce solutions supporting the telehealth sector, the compliance transformation is creating demand for regulatory affairs professionals, healthcare attorneys, and compliance officers with telehealth-specific expertise, a growing specialty within the regulatory compliance field that did not exist at significant scale three years ago.